TEXAS Trial

• Research type

  Research Study

• Full title

  TEXtural Analysis after Stereotactic radiotherapy in lung cancer

• IRAS ID

  198187

• Contact name

  Veni Ezhil

• Contact email

  veniezhil@nhs.net

• Sponsor organisation

  Royal Surrey County Hospital

• Duration of Study in the UK

  0 years, 2 months, 2 days

• Research summary

  Stereotactic ablative body radiotherapy (SABR) is a way of delivering high dose x-rays in a small number of treatments to shrink and control primary lung tumours. Standard radical radiotherapy is delivered in 5 daily doses each week for 4-6 weeks. SABR delivers a higher dose than standard radiotherapy in fewer doses. SABR aims to ablate the tumour and replace it with scar tissue. It can be difficult to distinguish between tumour and inflammation after radiotherapy. The aim of this study is to see if advanced analysis of post treatment CT scans allows easier detection of tumour recurrence. This will be achieved by comparing patients whose tumour had recurred with tumours that hadn't recurred.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  17/SC/0361

• Date of REC Opinion

  28 Jul 2017

• REC opinion

  Favourable Opinion